Navigation Links
Concerns Regarding Overstenting Will Limit the US Market for Interventional Cardiology Devices Through 2022
Date:12/11/2013

TORONTO, Dec. 11, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for interventional cardiology (IC) devices will be hindered by ongoing concerns over overstenting and the appropriate use of percutaneous coronary intervention (PCI). As a result, PCI volumes will continue to decline through 2018 before stabilizing. However, total IC device revenues will continue to fall through 2022 due to cost sensitivity and healthcare reforms.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

In this declining market, technological innovation will offer the best opportunity for companies to gain revenues. This has been most evident within the coronary stent segment. Abbott is expected to gain approval for the first bioresorbable vascular scaffold (BVS), ABSORB, in 2017; ABSORB received CE marking in Europe in 2011, and there is already significant interest in this device among US physicians. This product features a scaffold made of a polymer that completely dissolves in the vasculature over time, allowing the vessel to heal and return to normal. BVS are expected to offer clinical results similar to drug-eluting stents (DES), while supporting an improved safety profile. Although this product will initially be priced at a premium and will face significant competition from DES, ABSORB represents a major innovation and is likely to capture share within the coronary stent segment.

"A number of other stent technologies are expected to enter the market through 2022, many from smaller competitors focusing on niche segments," said MRG Senior Analyst Ian Swanson. "For example, Tryton Medical's TRYTON is a dedicated bifurcation stent, currently in clinical trials. InspireMD is developing a stent specifically designed to treat ST-segment elevation myocardial infarction patients. Similarly, STENTYS' product will be a self-apposing, self-expanding stent designed to treat patients suffering from acute myocardial infarction. Each of these devices is aimed at a specific difficult-to-treat patient niche and seeks to offer improved treatment options over currently available devices."

Millennium Research Group's US Markets for Interventional Cardiology Devices 2014 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty balloon catheters, accessory devices, intravascular imaging and pressure guidewires and coronary atherectomy devices in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
2. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. Obama administrations Plan B Decision Ignores Safety, Parental Rights Concerns
4. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
5. Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
6. DePuy Settlement News In Bellwether Case Concerns Plaintiffs Of The Hip Recall
7. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
8. New Study Answers CMS/USPSTF Concerns for CT Colonography Screening Reimbursement: It is a Viable Option for the Medicare-Aged Population
9. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
10. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
11. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Breast Cancer Therapeutics in Asia-Pacific Markets to ... (APAC) breast cancer market will experience considerable expansion from ... a Compound Annual Growth Rate (CAGR) of 8.5%. --> ... - states that the Asia-Pacific (APAC) ... in 2014 to $3.4 billion by 2021, at a Compound ...
(Date:2/11/2016)... , February 11, 2016 ... at Worldwide Clinical Trials, will present at this year,s Summit ... the Hyatt Regency in Miami, FL. ... partnerships to optimize study execution, supporting SCOPE,s "Improving Site Study ... take place on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology:
(Date:2/12/2016)... SAN LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast ... purpose of this dance is to provide a night of fun for teens with and ... to help everyone feel welcomed and included at the event. The dance will take place ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Basketball is a ... integral part of the Peety PoppersTM series, sign language translation is featured in the ... health and wellness in Peety PoppersTM lessons has a sign language translator to teach ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Dignity Health named ... Hospital Emergency Room –Mesa. The new facility is licensed under Dignity Health ... “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency room ...
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... According ... System, a product marketed as a weight loss dietary supplement, is being recalled due ... group Beverly Hills Physicians, because there is not a single supplement on the market ...
(Date:2/11/2016)... ... 2016 , ... Registered nurses, licensed practical nurses and nursing aides who treat ... Act, Time to Heal” on Thursday, February 25 from 9:00 to 11:00 a.m. at ... Chedda, president of ANSA Consultants, who will discuss clinical best practices throughout the continuum ...
Breaking Medicine News(10 mins):